Last reviewed · How we verify
epoetin alfa + packed RBC transfusion
epoetin alfa + packed RBC transfusion is a erythropoiesis-stimulating protein Small molecule drug developed by Janssen Research & Development, LLC. It is currently in Phase 3 development for Treatment of anemia associated with chronic kidney disease, chemotherapy-induced anemia, and HIV-associated anemia.
Epoetin alfa stimulates erythropoiesis by binding to the erythropoietin receptor, promoting the production of red blood cells.
Epoetin alfa stimulates erythropoiesis by binding to the erythropoietin receptor, promoting the production of red blood cells. Used for Treatment of anemia associated with chronic kidney disease, chemotherapy-induced anemia, and HIV-associated anemia.
At a glance
| Generic name | epoetin alfa + packed RBC transfusion |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Drug class | erythropoiesis-stimulating protein |
| Target | erythropoietin receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Epoetin alfa is an erythropoiesis-stimulating protein that mimics the action of endogenous erythropoietin, which is a hormone that regulates red blood cell production. By binding to the erythropoietin receptor, epoetin alfa triggers a cascade of intracellular signaling events that ultimately lead to the proliferation and differentiation of erythroid progenitor cells, resulting in increased red blood cell production.
Approved indications
- Treatment of anemia associated with chronic kidney disease, chemotherapy-induced anemia, and HIV-associated anemia
Common side effects
- Thromboembolic events
- Hypertension
- Headache
Key clinical trials
- A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy (PHASE3)
- The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- epoetin alfa + packed RBC transfusion CI brief — competitive landscape report
- epoetin alfa + packed RBC transfusion updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI
Frequently asked questions about epoetin alfa + packed RBC transfusion
What is epoetin alfa + packed RBC transfusion?
How does epoetin alfa + packed RBC transfusion work?
What is epoetin alfa + packed RBC transfusion used for?
Who makes epoetin alfa + packed RBC transfusion?
What drug class is epoetin alfa + packed RBC transfusion in?
What development phase is epoetin alfa + packed RBC transfusion in?
What are the side effects of epoetin alfa + packed RBC transfusion?
What does epoetin alfa + packed RBC transfusion target?
Related
- Drug class: All erythropoiesis-stimulating protein drugs
- Target: All drugs targeting erythropoietin receptor
- Manufacturer: Janssen Research & Development, LLC — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Treatment of anemia associated with chronic kidney disease, chemotherapy-induced anemia, and HIV-associated anemia
- Compare: epoetin alfa + packed RBC transfusion vs similar drugs
- Pricing: epoetin alfa + packed RBC transfusion cost, discount & access